AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25012727
Drug: Intramuscular pasireotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular pasireotide long-acting release
Trial: 17143047
Drug: Over-the-counter multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-the-counter multivitamin supplements containing vitamin K1
Trial: 16274381
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg 17‐beta estradiol for 36 months
Trial: 12018742
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose Therapy (HDT)
Trial: 12018742
Drug: Conventional Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Chemotherapy (CCT)
Trial: 7587973
Drug: AUDADIS drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUDADIS drug module
Trial: 2078484
Drug: Intensification-discontinuation arm
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification-discontinuation arm (B)
Trial: 29749718
Drug: Test acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test acetaminophen product available in Mexico
Trial: 29749718
Drug: Reference 500‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference 500‐mg acetaminophen product
Trial: 24728665
Drug: Peretinoin 600
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peretinoin 600 mg/day
Trial: 24728665
Drug: Peretinoin 300
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peretinoin 300 mg/day
Trial: 23668921
Drug: Postoperative subacromial
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative subacromial infusion catheter filled with 0.5% bupivacaine without epinephrine
Trial: 23668921
Drug: Postoperative subacromial
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative subacromial infusion catheter filled with saline solution
Trial: 23668921
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative subacromial infusion catheter
Trial: 23668921
Drug: Mean daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean daily oxycodone consumption
Trial: 21545606
Drug: A3309 (0.1-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A3309 (0.1-10 mg/day)
Trial: 15500197
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg acetylsalicylic acid (ASA) + 60 mg pseudoephedrine (PSE)
Trial: 15500197
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ASA + 30 mg PSE
Trial: 15500197
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg paracetamol + 60 mg PSE (active control)
Trial: 11222797
Drug: Monotherapy initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monotherapy initiation trials
Trial: 7946584
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiation treatment
Trial: 7946584
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment (at 8 months)
Trial: 7946584
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (after 3 months)
Trial: 30678556
Drug: High-ending tune
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-ending tune (L*+H L‐!H%)
Trial: 30678556
Drug: Flat-ending tune
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flat-ending tune (L+H* L‐L%)
Trial: 25049247
Drug: Posaconazole tablets
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole tablets
Trial: 25760679
Drug: Phenylephrine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (100 μg + 0.5 μg kg(‐1) min(‐1))
Trial: 23796191
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care intervention (20-minute session of behavioural change counselling, with potential referral to motivational enhancement therapy and local specialist alcohol services)
Trial: 21362268
Drug: Transforming growth
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforming growth factor β receptor type II (TGFBRII) overexpression
Trial: 11210993
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin plus bedtime subcutaneous ultralente insulin injection
Trial: 11210993
Drug: Usual insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual insulin regimen of two to three injections per day
Trial: 9701387
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1000 mg 3 times per day)
Trial: 8027275
Drug: Buserelin (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin (twice a day for 15 days)
Trial: 8027275
Drug: Triptorelin (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (3.75 mg single dose 15 days before stimulation)
Trial: 8027275
Drug: Triptorelin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (0.1 mg daily for 4 weeks before stimulation)
Trial: 2563730
Drug: BIM 23014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIM 23014 (2 mg/12 h, constant sc infusion)
Trial: 2563730
Drug: BIM 23014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIM 23014 (2 mg/12 h, constant sc infusion) with GHRH (10 ng/kg.min iv)
Trial: 4053513
Drug: Aspirin administration
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin administration
Trial: 31559844
Drug: Fascial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascial therapy
Trial: 24238397
Drug: SMS reminders
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS reminders (daily messages reminding them of aspects regarding taking their medication)
Trial: 12951885
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g glucose ingestion during oral glucose tolerance test
Trial: 7632121
Drug: Psychoeducational multiple‐family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational multiple‐family group treatment
Trial: 7632121
Drug: Psychoeducational single‐family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational single‐family treatment
Trial: 2565687
Drug: Isradipine alone
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine alone (1.25 and 2.5 mg twice daily)
Trial: 2565687
Drug: Isradipine with
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine with guanfacine (1 mg daily after 8 weeks)
Trial: 28918754
Drug: Ferritin level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferritin level above 4420 ng/ml
Trial: 19116322
Drug: 1.05 g
RxNorm normalized name: AVC 1.05 GM Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.05 g E-EPA/d plus 0.15 g ethyl-docosahexaenoic acid/d (n = 59)
Trial: 11161541
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (parenteral nutrition without lipids)
Trial: 11161541
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (parenteral nutrition with lipids)
Trial: 9550543
Drug: Selective β1‐adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective β1‐adrenoceptor antagonist atenolol (0.062 mg · kg‐1 body weight) administered immediately after exercise (EXAT)
Trial: 9550543
Drug: Nonselective β‐adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonselective β‐adrenoceptor antagonist propranolol (0.15 mg · kg‐1 body weight) administered after exercise (EXPRO)
Trial: 9550543
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection instead of β‐antagonist (EX)
Trial: 9550543
Drug: Control with
RxNorm normalized name: Azo Bladder Control With Go Less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control with selective β1‐adrenoceptor antagonist atenolol (REAT)
Trial: 9550543
Drug: Control with
RxNorm normalized name: Azo Bladder Control With Go Less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control with nonselective β‐adrenoceptor antagonist propranolol (REPRO)
Trial: 2679236
Drug: Nicardipine (NIC)
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine (NIC) treatment group
Trial: 2679236
Drug: NIC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIC treatment group with impaired LV function
Trial: 2679236
Drug: NIC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIC treatment group
Trial: 630909
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg fenfluramine plus a 1600 calorie diet
Trial: 630909
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg fenfluramine
Trial: 20672256
Drug: Group music
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group music intervention (12 sessions of 30 minutes each, twice a week for 6 weeks)
Trial: 16784179
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg per day)
Trial: 8953683
Drug: Biapenem 500
RxNorm normalized name: biapenem
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biapenem 500 mg every 8 h
Trial: 8953683
Drug: Imipenem/cilastatin 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin 500 mg/500 mg every 6 h
Trial: 9023498
Drug: Lysine acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetylsalicylate 1.8 g
Trial: 12974995
Drug: Placebo monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo monotherapy
Trial: 8084248
Drug: Oral protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral protein load in Group I (reflux patients)
Trial: 8084248
Drug: Oral protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral protein load in Group II (urinary infection patients)
Trial: 8084248
Drug: Oral protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral protein load in Group III (healthy controls)
Trial: 16435613
Drug: Spinal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal morphine
Trial: 27882820
Drug: AXL1717 (AXL)
RxNorm normalized name: Humax axl adc
DrugBank: Enapotamab vedotin (DB16156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXL1717 (AXL) 300 or 400 mg daily BID
Trial: 27882820
Drug: Docetaxel (DCT)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (DCT) 75 mg/m2 in three-week cycles
Trial: 24386809
Drug: Long-term oxygen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oxygen therapy (LTOT) via nasal cannula, administered continuously every day for one year.
Trial: 22893497
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise training (SET) on top of best medical treatment (BMT) for 6 months
Trial: 15532380
Drug: Carvedilol (24.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (24.4 +/- 2.0 mg/day) + Fosinopril (2.5-40 mg/day)
Trial: 15532380
Drug: Atenolol (44.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (44.1 +/- 5.1 mg/day) + Fosinopril (2.5-40 mg/day)
Trial: 2670719
Drug: Magaldrate (antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magaldrate (antacid poor in aluminum)
Trial: 2670719
Drug: Compound M
RxNorm normalized name: benzoin compound MISCELL TINCTURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound M 70 (antacid rich in aluminum)
Trial: 31526767
Drug: Levodopa medication
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa medication (on medication)
Trial: 31526767
Drug: Training off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training off levodopa medication (off medication)
Trial: 26626800
Drug: S-1 (40-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (40-60 mg/m2 twice daily) for 2 weeks, followed by S-1 and oxaliplatin (100 mg/m2) for 8 cycles
Trial: 25223844
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT), manualized exposure-based
Trial: 21831418
Drug: Carboplatin and
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and paclitaxel doublet chemotherapy (4 cycles: 3 weeks on treatment, 1 week off; carboplatin on day 1, paclitaxel on days 1, 8, and 15)
Trial: 21831418
Drug: Vinorelbine or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine or gemcitabine monotherapy (5 cycles: 2 weeks on treatment, 1 week off)
Trial: 21831418
Drug: Doublet chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublet chemotherapy
Trial: 10722036
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (66 mg/kg per hour)
Trial: 1333105
Drug: Unfractionated (UF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractionated (UF) heparin 5000 IU three times daily for 10 days
Trial: 1333105
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight (LMW) heparin (CY 216 D) 3100 IU once daily for 10 days
Trial: 27687678
Drug: 20 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 cisplatin on 5 days every 4 weeks (group A)
Trial: 27687678
Drug: 30-40 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-40 mg/m2 cisplatin weekly (group B)
Trial: 21810108
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list control (delayed treatment group)
Trial: 10912691
Drug: Topical adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical adrenaline application after myringotomy before tympanostomy tube placement
Trial: 8259772
Drug: Etidronate therapy
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etidronate therapy (400 mg daily for 14 days, phosphate 1.0 g twice daily for 3 days, calcium 500 mg daily for the remainder of each 91-day cycle)
Trial: 20434046
Drug: Etidronate therapy
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etidronate therapy
Trial: 8259772
Drug: Open-label intermittent
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label intermittent cyclic etidronate therapy
Trial: 3897204
Drug: Fluoxetine (55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (55 mg/day)
Trial: 3897204
Drug: Amitriptyline (159
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (159 mg/day)
Trial: 31818628
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg once daily for 3 weeks)
Trial: 28177189
Drug: High cortisol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cortisol (c. 1400 nM) with high insulin
Trial: 28177189
Drug: High cortisol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cortisol (c. 1400 nM) with low insulin
Trial: 28177189
Drug: High cortisol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cortisol (c. 1400 nM) in vitro with insulin
Trial: 28177189
Drug: High cortisol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cortisol (c. 1400 nM) in vitro without insulin
Trial: 24124684
Drug: One-stop diagnosis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One-stop diagnosis and treatment group (CTU 3-D reconstruction, ultrasound and radiology guided puncture followed by PCNL)
Trial: 12212157
Drug: External irradiation
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External irradiation and after-load intracavitary radiation in combination with traditional Chinese medicine (EIAIRC)
Trial: 12212157
Drug: External irradiation
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External irradiation plus traditional Chinese medicine (EIC)
Trial: 8837569
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (ischemia-none group)
Trial: 1450659
Drug: lodoxamide 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lodoxamide 0.1% ophthalmic solution
Trial: 1450659
Drug: sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium cromoglycate 2% ophthalmic solution
Trial: 6375407
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Doxycycline (DX)
Trial: 23845740
Drug: Metformin (1700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1700 mg/die)
Trial: 23845740
Drug: Metformin (1700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1700 mg/die) plus low-dose spironolactone (25 mg/die)
Trial: 20148739
Drug: Metformin (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1500 mg)
Trial: 20148739
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Lifestyle modification
Trial: 9932655
Drug: 33 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33 mmol/L bicarbonate solution
Trial: 9932655
Drug: 40 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mmol/L lactate solution
Trial: 7708260
Drug: Ultrafiltration rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrafiltration rate of 60 ml/min with dialysate calcium concentration of 1.63 mmol/l
Trial: 7708260
Drug: Ultrafiltration rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrafiltration rate of 100 ml/min with dialysate calcium concentration of 1.63 mmol/l
Trial: 7708260
Drug: Infusion rate
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rate of 2.5 l/h with dialysate calcium concentration of 1.63 mmol/l
Trial: 7708260
Drug: Infusion rate
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rate of 5 l/h with dialysate calcium concentration of 1.63 mmol/l
Trial: 7708260
Drug: Infusion rate
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rate of 2.5 l/h with dialysate calcium concentration of 1.5 mmol/l
Trial: 7708260
Drug: Infusion rate
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rate of 5 l/h with dialysate calcium concentration of 1.5 mmol/l
Trial: 7708260
Drug: Infusion rate
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rate of 2.5 l/h with dialysate calcium concentration of 1.25 mmol/l
Trial: 7708260
Drug: Infusion rate
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rate of 5 l/h with dialysate calcium concentration of 1.25 mmol/l
Trial: 2658462
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate treatment (both concentrations)
Trial: 30406819
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of amlodipine (10 mg/day) plus medium dose of ARB (high-AML)
Trial: 30406819
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose of amlodipine (5 mg/day) plus high dose of ARB (high-ARB)
Trial: 26073354
Drug: Linagliptin 2.5
RxNorm normalized name: linagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 2.5 mg/metformin 850 mg